# US 2014/0193881 A1 · Novel adamts-13 mutant > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0193881 A1 - Document ID: US20140193881A1 - Status: Published application - Kind: A1 - Application number: 14/166,177 - Filed: 2014-01-28 - Published: 2014-07-10 - Earliest claimed: 2007-06-22 - Assignees: The Chemo-Sero-Therapeutic Research Institute - Applicants: The Chemo-Sero-Therapeutic Research Institute - Inventors: Kenji SOEJIMA - Web page: https://patentgrep.com/patent/US20140193881A1 ## CPC - C12N 9/6489: {Metalloendopeptidases (3.4.24)} - A61K 38/4886: {Metalloendopeptidases (3.4.24), e.g. collagenase} - A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors - A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis - A61P 13/12: of the kidneys - A61P 37/02: Immunomodulators - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - C12Y 304/24087: ADAMTS13 endopeptidase (3.4.24.87) - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C12Y: ENZYMES ## Abstract An enhanced disintegrin-like domain, and metalloprotease, with an isolated human thrombospondin type 1 motif, member 13 (ADAMTS-13) that includes substitutions at one or more positions in the isolated human ADAMTS-13. ## Claims ### Claim 1 (canceled) ### Claim 2 An ADAMTS-13 (a disintegrin-like domain, and metalloprotease, with an isolated human thrombospondin type 1 motif, member 13) mutant, comprising a substitution of the following positions in the isolated human ADAMTS-13 with a different amino acid: aspartic acid at position 287, aspartic acid at position 298, glutamic acid at position 309, arginine at position 312, lysine at position 318, glutamic acid at position 327, aspartic acid at position 340, glutamic acid at position 363, lysine at position 364, lysine at position 368, arginine at position 370, arginine at position 372, arginine at position 386, arginine at position 452, arginine at position 459, glutamic acid at position 492, lysine at position 497, aspartic acid at position 500, aspartic acid at position 504, arginine at position 514, glutamic acid at position 515, aspartic acid at position 516, arginine at position 535, aspartic acid at position 537, arginine at position 544, aspartic acid at position 551, asparagine at position 552, arginine at position 558, lysine at position 559, arginine at position 566, arginine at position 568, glutamic acid at position 569, asparagine at position 579, lysine at position 608, asparagine at position 614, arginine at position 625, arginine at position 629, glutamic acid at position 634, aspartic acid at position 635, arginine at position 636, arginine at position 639, arginine at position 644, glutamic acid at position 651, arginine at position 659, glutamic acid at position 663, glutamic acid at position 664, asparagine at position 667, arginine at position 670, or arginine at position 683 in the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO:1. ### Claim 3 (depends on 2) The ADAMTS-13 mutant according to claim 2, comprising a substitution of arginine at position 312, lysine at position 318, arginine at position 568, glutamic acid at position 569, asparagine at position 579, lysine at position 608, asparagine at position 614, glutamic acid at position 634, aspartic acid at position 635 or arginine at position 639, glutamic acid at position 644, or asparagine at position 667. ### Claim 4 (depends on 2) The ADAMTS-13 mutant according to claim 2, comprising a substitution of arginine at position 312, lysine at position 318, arginine at position 568, glutamic acid at position 569, asparagine at position 579, lysine at position 608, asparagine at position 614, glutamic acid at position 634, aspartic acid at position 635, arginine at position 639, arginine at position 644, glutamic acid at position 651, arginine at position 659, glutamic acid at position 663, glutamic acid at position 664, asparagine at position 667, or arginine at position 670. ### Claim 5 (depends on 2) The ADAMTS-13 mutant according to claim 2, wherein the different amino acid is an uncharged amino acid. ### Claim 6 (depends on 3) The ADAMTS-13 mutant according to claim 3, wherein the different amino acid is an uncharged amino acid. ### Claim 7 (depends on 4) The ADAMTS-13 mutant according to claim 4, wherein the different amino acid is an uncharged amino acid. ### Claim 8 (depends on 5) The ADAMTS-13 mutant according to claim 5, wherein the uncharged amino acid is selected from the group consisting of alanine, glycine, proline, serine and threonine. ### Claim 9 (depends on 6) The ADAMTS-13 mutant according to claim 6, wherein the uncharged amino acid is selected from the group consisting of alanine, glycine, proline, serine and threonine. ### Claim 10 (depends on 7) The ADAMTS-13 mutant according to claim 7, wherein the uncharged amino acid is selected from the group consisting of alanine, glycine, proline, serine and threonine.